Keyword: Kymriah (tisagenlecleucel)
The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.
Novartis continues to wrestle with manufacturing issues for Kymriah, a problem that is hampering Kymriah sales.
Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its next-generation cell and gene therapies.
Gilead and Novartis are working to ramp up launches of their CAR-T drugs, and both companies are hoping longer-term data will help do the trick.
NICE may have rejected it, but thanks to a new discount, Yescarta's beating archrival Kymriah to adult lymphoma patients on England's health service.
Tasuku Honjo wins Nobel Prize for PD-1 research; Legend fires back at CAR-T data fabrication allegation; Takeda alumni demand more on Shire buyout.
Novartis is looking ahead to China for introduction of its CAR-T treatment Kymriah with a deal for manufacturing there.
NICE rejected Novartis' Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies.
Juno didn't immediately report CAR-T trial deaths, investors argued in a lawsuit, and now the sides have inked a $24 million settlement.